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A Prospective Multicenter Study of Microbiologically  
Defined Infections in Pediatric Cancer Patients  
With Fever and Neutropenia
Swiss Pediatric Oncology Group 2003 Fever and Neutropenia Study
Philipp Agyeman, MD,*† Udo Kontny, MD,‡§ David Nadal, MD,¶ Kurt Leibundgut,  MD,* Felix Niggli,  MD,‖ 
Arne Simon,  MD,** Andreas Kronenberg,  MD,† †† Reno Frei,  MD,‡‡ Hugo Escobar, MD,‡ §§  
Thomas Kühne,  MD,¶¶ Maja Beck-Popovic, MD,‖‖ Nicole Bodmer,  MD,‖ and Roland A. Ammann,  MD*
Background: Fever and neutropenia (FN) often complicate anticancer 
treatment and can be caused by potentially fatal infections. Knowledge of 
pathogen distribution is paramount for optimal patient management.
Methods: Microbiologically defined infections (MDI) in pediatric cancer 
patients presenting with FN by nonmyeloablative chemotherapy enrolled in a 
prospective multicenter study were analyzed. Effectiveness of empiric antibi-
otic therapy in FN episodes with bacteremia was assessed taking into consid-
eration recently published treatment guidelines for pediatric patients with FN.
Results: MDI were identified in a minority (22%) of pediatric cancer patients 
with FN. In patients with, compared with patients without MDI, fever [median, 
5 (interquartile range: 3–8) vs. 2 (interquartile range: 1–3) days, P < 0.001] and 
hospitalization [10 (6–14) vs. 5 (3–8) days, P < 0.001] lasted longer, transfer 
to the intensive care unit was more likely [13 of 95 (14%) vs. 7 of 346 (2.0%), 
P < 0.001], and antibiotics were given longer [10 (7–14) vs. 5 (4–7) days, P < 
0.001]. Empiric antibiotic therapy in FN episodes with bacteremia was highly 
effective if not only intrinsic and reported antimicrobial susceptibilities were 
considered but also the purposeful omission of coverage for coagulase-negative 
staphylococci and enterococci was taken into account [81% (95% confidence 
interval: 68–90) vs. 96.6% (95% confidence interval: 87–99.4), P = 0.004].
Conclusions: MDI were identified in a minority of FN episodes but they 
significantly affected management and the clinical course of pediatric can-
cer patients. Compliance with published guidelines was associated with 
effectiveness of empiric antibiotic therapy in FN episodes with bacteremia.
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(Pediatr Infect Dis J 2014;33:e219–e225)
Fever and neutropenia (FN) frequently complicate anticancer treatment and can be caused by potentially fatal infections.1 
Successful management of FN is based on empiric antimicrobial 
treatment.2 Knowledge of expected pathogens, local antimicrobial 
susceptibility patterns, and the clinical course of FN episodes is 
important to optimize empiric treatment. Shifts in the spectrum of 
bacterial pathogens causing infections in patients with cancer and 
the emergence of resistant pathogens fuel the need for a constant 
surveillance of local conditions.
The multicenter prospective Swiss Pediatric Oncology 
Group (SPOG) 2003 FN study was set up to develop prediction 
scores for adverse events3 and bacteremia4 and to do a randomized 
controlled trial of outpatient oral versus inpatient intravenous anti-
biotics in selected low-risk episodes of FN.5 We describe here FN 
episodes with microbiologically defined infections (MDI), their 
management and clinical course and the pathogens isolated in epi-
sodes with MDI in the SPOG 2003 FN study.
PATIENTS AND METHODS
Study Design
Details of the study design of the prospective multicenter SPOG 
2003 FN study have been previously published.3,5 In brief, patients 
with cancer 1–18 years of age presenting with FN after nonmyeloa-
blative chemotherapy were recruited by pediatric oncology centers in 
Switzerland and Germany between January 2004 and December 2007. 
Local and national ethics committees had approved the study.
Patients and Management of FN
In- and outpatients with cancer 1–18 years of age were 
included in the study if they had fever, defined either as axillary 
temperature ≥ 38.5°C once or ≥ 38.0°C for ≥ 2 hours,6 and neutro-
penia, defined as an absolute neutrophil count ≤ 0.5 G/L.6 At pres-
entation with FN, all patients underwent a physical examination 
and blood was sampled for blood cultures and differential blood 
count. Empiric intravenous broad-spectrum antimicrobial therapy 
covering for Gram-positive [except methicillin-resistant Staphy-
lococcus aureus, coagulase-negative staphylococci (CoNS) and 
Enterococcus species] and Gram-negative bacteria was started. The 
treating physician decided on further diagnostic procedures and 
supportive measures. Patients were observed as inpatients and reas-
sessed within 8–24 hours after admission. If prespecified restrictive 
 low-risk criteria were fulfilled, they were offered to participate in 
the randomized controlled trial mentioned above (NCT00107081).5 
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However, in the vast majority of episodes, patients stayed hospi-
talized and were offered all standard diagnostic and therapeutic 
measures. This included escalation of antimicrobial treatment in 
patients with persistent fever to cover for CoNS, methicillin-resist-
ant Staphylococcus aureus, enterococci, resistant Gram-negative 
bacteria and eventually fungal infections.
Participating Centers
Eight pediatric oncology centers from Switzerland (cent-
ers A to E) and Germany (centers F to H) participated in the 
SPOG 2003 FN study. Centers A, B and C were located in the 
 German-speaking part and centers D and E in the French-speaking 
part of Switzerland. All centers reported numbers and etiology of 
MDI, and results of antimicrobial susceptibility testing of bacterial 
pathogens isolated in blood cultures. Center A additionally reported 
time to positivity of pathogens isolated in blood cultures and was 
the only center to implement a low-threshold testing strategy for 
viral respiratory infections. There were no differences in antibiotic 
prophylaxis regimens between centers. Only standard pneumocys-
tis jirovecii prophylaxis was used in this study.
Microbiologically Defined Infections
Details on MDI definitions have been published.3,4 Essen-
tially, initial aerobic and anaerobic blood cultures were taken at 
presentation with FN before starting antimicrobial therapy in 
all patients. Further blood cultures were taken daily if fever per-
sisted or the patient experienced shaking chills. Blood cultures 
were drawn from existing central venous catheters, if present, or 
a peripheral vein. Peripheral and central blood cultures were not 
performed in parallel. Bacteremia was defined as at least 1 positive 
blood culture, irrespective of the pathogen detected, using a qualita-
tive automated culture system (BacT/ALERT, bioMérieux, Geneva, 
Switzerland; or BACTEC, Becton Dickinson, Basel, Switzerland).4 
For the analysis of time to positivity in center A, the time from 
loading of the blood culture vial into the incubator until detection 
of growth of microorganisms was considered. All pathogens identi-
fied in blood cultures were analyzed separately, provided they dif-
fered in species, morphology, antimicrobial susceptibility testing or 
time point of sampling. Bacterial infections other than bacteremia 
were defined by a pathogen isolated from a normally sterile body 
fluid or compartment.3 Viral infections were defined by the detec-
tion of a viral antigen7 or product of polymerase chain reaction by 
a validated microbiologic method. For this analysis, invasive fungal 
infections were defined according to the revised definitions of inva-
sive fungal disease from the European Organization for Research 
and Treatment of Cancer/Invasive Fungal Infections Cooperative 
Group and the National Institute of Allergy and Infectious Diseases 
Mycoses Study Group (EORTC/MSG) Consensus Group.8
Effectiveness of Empiric Antibiotic Treatment in 
FN Episodes With Bacteremia
Effectiveness of empiric antibiotic therapy was assessed 
in 3 different ways. In vitro effectiveness was assessed based on 
reported and intrinsic antimicrobial susceptibilities to the antibiot-
ics given on the day of sampling of the first positive blood culture. 
Effectiveness because of compliance with pediatric FN guidelines 
was defined by in vitro effectiveness restricted to pathogens to be 
covered by empiric antibiotic therapy according to current treat-
ment recommendations for pediatric FN.9,10 Therefore, effective-
ness because of compliance with pediatric FN guidelines would be 
present even if a pathogen not covered by empiric antibiotic therapy 
(eg, CoNS or enterococci) was diagnosed from blood cultures sam-
pled in the first 48 hours. Finally, microbiologic effectiveness was 
defined by the growth of bacterial pathogens in any blood culture 
after the initiation of empiric antibiotic therapy. 
Comparison of Bacteremia Causing Pathogens 
to the Swiss Centre for Antibiotic Resistance 
Database
The Swiss Centre for Antibiotic Resistance (ANRESIS)11,12 
is an ongoing laboratory-based representative surveillance system 
collecting antibiotic resistance data of actually 20 Swiss microbiol-
ogy laboratories. For this analysis, the distribution and antibiotic 
resistance of blood-borne pathogens detected in centers A, B and C 
were compared with the corresponding population in the ANRESIS 
database. Data of centers D and E, located in the French-speaking 
part of Switzerland, were excluded from this analysis because of the 
very low numbers of FN episodes with bacteremia reported (1 and 
4 episodes, respectively). The ANRESIS population was defined as 
all positive blood cultures in children 2–15 years of age isolated 
during the years 2004–2007 in 1 of the Swiss German university 
children’s hospitals participating also in the SPOG 2003 FN study. 
MDI with the same organism and the same resistance profile in the 
same patient were counted as different infections if the time inter-
val between the 2 respective blood cultures exceeded 7 days. For 
this comparison, CoNS were judged as contaminants and excluded 
from analysis if isolated once within 7 days (ANRESIS popula-
tion) or if clinically judged as nonsignificant, that is, not treated 
or treated <5 days with a glycopeptide antibiotic (SPOG 2003 FN 
study).
Statistics
Proportions and their exact 95% Blyth-Still-Casella con-
fidence intervals (95% CI) were calculated. Nonparametric exact 
2-sided tests were used throughout. Specifically, the Fisher test, 
Fisher-Freeman-Halton test, Mann-Whitney U test,  Kruskall-Wallis 
test with Dunn’s multiple comparison tests and exact odds ratios 
(OR) of binomial proportions were calculated where applicable. 
For all statistical analyses, a 2-sided P value of 0.05 was consid-
ered significant. Statistical analyses were performed with Graph-
Pad Prism 6.0 (GraphPad Software, La Jolla, CA) and StatXact 10 
(Cytel Inc., Cambridge, MA).
RESULTS
Patients and Episodes of FN
Eight German and Swiss pediatric oncology centers reported 
a total of 472 episodes of FN. Eligibility criteria were not fulfilled in 
25 (5.3%) episodes, and follow up was missing in 4 (0.8%). Addi-
tionally, 2 (0.4%) duplicate episodes were excluded. The remaining 
441 (93.4%) FN episodes were analyzed here. Centers A, B and C 
reported 171 (39%), 153 (35%) and 9 (2%) FN episodes, respec-
tively, whereas centers D to H reported the remaining 108 (24%) 
FN episodes. They occurred in 209 patients [median, 2 episodes per 
patient, interquartile range (IQR), 1–3], with a median age of 7.0 
years (IQR: 3.9–11.7) at the first FN episode. Further details have 
been published.3,4,13 An MDI was identified in 95 (22%; 95% CI: 
18–26) of these 441 FN episodes, bacteremia in 67 (15%; 95% CI: 
12–19), a focal bacterial infection in 8 (1.8%; 95% CI: 0.8–3.5), a 
viral infection in 29 (6.6%; 95% CI: 4.5–9.2) and a fungal infection 
in 5 (1.1%; 95% CI: 0.4–2.6). In 12 (2.7%; 95% CI: 1.5–4.6) of 
these 441 FN episodes, >1 MDI was identified.
Clinical Course of FN Episodes
In FN episodes with versus without MDI fever per-
sisted for a longer time [median, 5 (IQR: 3–8) vs. 2 (IQR: 1–3) 
days, P < 0.001], patients were hospitalized longer [median, 10 
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(IQR: 6–14) vs. 5 (IQR: 3–8) days, P < 0.001] and transferred more 
often to the intensive care unit [ICU; 13 of 95 (14%) vs. 7 of 346 
(2.0%), OR: 7.7, 95% CI 2.7–23.3, P < 0.001]. Additionally, anti-
microbial treatment in FN episodes with versus without MDI was 
more intensive as exemplified by a longer duration of intravenous 
antibiotic administration [median, 10 (IQR: 7–14) vs. 5 (IQR: 4–7) 
days, P < 0.001], higher proportion of empiric antibiotic therapy 
escalation [67 of 95 (71%) vs. 106 of 346 (31%), OR: 5.4, 95% CI: 
3.2–9.2, P < 0.001] and a higher proportion of empiric antifungal 
treatment [30 of 95 (32%) vs. 37 of 346 (11%), OR: 3.9, 95% CI: 
2.1–6.9, P < 0.001]. Table 1 shows clinical- and management-
related characteristics for the different categories of MDI compared 
with FN episodes without MDI.
FN Episodes with Bacteremia
In 67 FN episodes with bacteremia, a total of 83 pathogens 
were identified; 54 (65%) Gram-positive bacteria and 29 (35%) 
Gram-negative bacteria (Table 2). There were no significant dif-
ferences in fever duration, hospitalization length, proportion 
transferred to the ICU, duration of intravenous antibiotic treat-
ment, escalation of antibiotic therapy and duration of escalated 
antibiotic therapy between Gram-positive and Gram-negative bac-
teria (details not shown). Antimicrobial susceptibility testing was 
available for 68 (82%) of 83 blood culture isolates, but the impor-
tant heterogeneity of susceptibility results available precluded 
meaningful comparisons. Methicillin-resistant Staphylococcus 
aureus,  vancomycin-resistant enterococci or extended-spectrum, 
β-lactamase producing Gram-negative bacteria were not reported.
Effectiveness of Empiric Antibiotic Therapy in FN 
Episodes With Bacteremia
Table 3 specifies in vitro effectiveness versus effective-
ness because of compliance with pediatric FN guidelines ver-
sus microbiologic effectiveness of empiric antibiotic therapy in 
the 67 FN episodes with bacteremia. In the 58 (87%) episodes 
with susceptibility results available, the effectiveness because 
of compliance with pediatric FN guidelines [56 of 58 episodes; 
96.6% (95% CI: 87–99.4)] was significantly higher than the in 
vitro effectiveness [47 of 58 episodes; 81% (95% CI: 68–90), 
P = 0.004] and the microbiologic effectiveness [45 of 58 epi-
sodes; 78% (95% CI: 64–87), P = 0.003]. CoNS bacteremia was 
the major reason for both in vitro [8 of 11 (73%)] and microbio-
logic [11 of 14 (79%)] noneffectiveness. Applying only micro-
biologic effectiveness criteria, the initial empiric therapy failed in 
10 (15%) of 67 FN episodes with bacteremia, while the escalated 
empiric therapy failed in 4 (7.7%) of 52 FN episodes. In 1 FN 
episode with clinical signs of a central venous catheter infection 
and empiric glycopeptide monotherapy, new Escherichia coli 
bacteremia was detected on day 3 of hospitalization. In both the 
in vitro and the microbiologic effectiveness scenarios, there were 
no significant differences in fever duration, hospitalization length 
and proportion transferred to the ICU between FN episodes with 
bacteremia treated with effective versus ineffective initial empiric 
antibiotic therapy (details not shown).
Of note, antibiotic therapy was escalated in 106 (31%) of 
346 FN episodes without MDI.
Time to Positivity in FN Episodes With Bacteremia
In center A, time to positivity was known in 33 (89%) of 
37 blood cultures (31 of 34 FN episodes). In 27 (82%) of these 33 
blood cultures, a pathogen grew within 24 hours. All blood cultures 
with a time to positivity >18 hours grew CoNS in monoculture 
(Fig. 1). Correspondingly, for blood cultures with monocultural 
growth of CoNS time to positivity [19.8 hours (IQR: 12.2–39)] 
was significantly longer than for blood cultures growing other 
Gram-positive bacteria [8.7 hours (IQR: 4.1–11.5), P = 0.021] and 
blood cultures growing Gram-negative bacteria [4.2 hours (IQR: 
2.2–4.9), P = 0.001]. Compared with blood cultures with polymi-
crobial growth, only a trend was noted [7.9 hours (IQR: 3.5–8.7), 
P = 0.051].
TABLE 1. Differences of Clinical and Management Characteristics in 441 FN Episodes According to the 
Microbiologically Defined Infection
Bacteremia  
Only  
(n = 55)
Viral Infection 
Only  
(n = 22)
Focal Bacterial, Fungal, 
and Mixed Infections  
(n = 18)
No Microbiologically 
Defined Infection  
(n = 346) P Value
Duration of fever (days) 4 (2– 6)* 4.5 (2– 7)* 9 (3–16.8)* 2 (1–3) <0.001†
Hospitalization length (days) 10 (8–13)* 7.5 (5–10)* 23.5 (6.8–30)* 5 (3–8) <0.001†
Episodes with transfer to ICU 2 of 55 (3.6%)‡ 2 of 22 (9.1%)‡ 9 of 18 (50%)* 7 of 346 (2.0%) <0.001§
Duration of intravenous antibiotic 
therapy (days)
11 (9–14)*¶ 6.5 (4.8–10.3) 16 (9.8–23.8)*¶ 5 (4–7) <0.001†
Episodes with escalation of antibiotic 
therapy
42 of 55 (76%)*¶ 10 of 22 (46%)‡ 15 of 18 (83%)* 106 of 346 (31%) <0.001§
Duration of escalated antibiotic 
therapy (days; n = 173)
10 (7–12)*
(n = 42)
6.5 (4.8–16) 
(n = 10)
13 (10–21)* 
(n = 15)
6 (4–8.3) 
(n =106)
<0.001†
Episodes with escalation of antibiotic 
 therapy of those with fever >48 h 
(n = 260)
36 of 46 (78%)* 10 of 18 (56%) 14 of 17 (82%)* 87 of 179 (49%) < 0.001§
Episodes with antifungal therapy 15 of 55 (27%)* 7 of 22 (32%)* 8 of 18 (44%)* 37 of 346 (11%) < 0.001§
Episodes with antifungal therapy of 
those with fever > 96 h (n = 105)
13 of 21 (62%) 7 of 11 (64%) 7 of 11 (64%) 25 of 62 (40%) 0.17§
C-reactive protein at presentation 
(mg/L) (n = 428)
47 (31–79) 
(n = 52)
26 (11–97) 
(n = 21)
42 (25–105.3)
(n = 18)
37 (15–82) 
(n = 337)
0.2†
Data are presented as median (IQR), unless otherwise indicated.
*Significantly different to the group with no microbiologically defined infection (Dunn’s multiple comparison test).
†Kruskall-Wallis test, significant differences between groups were estimated with Dunn’s multiple comparison test.
‡Significantly different to the group with focal bacterial, fungal, and mixed infections (Fisher exact test).
§Fisher-Freeman-Halton test, significant differences between groups were estimated with Fisher exact test.
¶ Significantly different to the group with viral infection solely (Dunn’s multiple comparison test).
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Comparison of Bacteremia Causing  
Pathogens to the Swiss Centre for  
Antibiotic Resistance Database
The distribution of pathogens in 58 (87%) of 67 FN epi-
sodes with bacteremia observed in 333 (76% of 441) FN episodes 
reported from centers A, B and C was significantly different from 
the distribution of pathogens causing bacteremia in the general 
pediatric population of the German-speaking part of Switzerland 
(P < 0.001; Table 4).
CoNS (21% vs. 9.8%, P = 0.023) and viridans group strep-
tococci (VGS) (29% vs. 9.3%, P < 0.001) were detected more fre-
quently in pediatric cancer patients with FN. In contrast, Strepto-
coccus pneumoniae (0% vs. 24%, P < 0.001) was detected more 
frequently in the general pediatric population. Antimicrobial resist-
ance did not differ significantly (details not shown).
Other MDI
A focal bacterial infection was microbiologically proven 
in 8 (1.8%) of 441 FN episodes (2 urinary tract infections, 3 
soft tissue infections and 3 pneumonias). A viral infection was 
TABLE 2. Positive Blood Culture Results Defining 
Bacteremia in 441 FN Episodes
All
Time of Blood 
 Culture  Sampling
< 48 h > 48 h
Bacteria cultured 83 68 15
  Gram-positive bacteria 54 40 14
   S. aureus 4 4
   CoNS 27 14 13
   Viridans group streptococci 20 20
   Enterococcus species 2 1 1
   Rothia mucilaginosa 1 1
  Gram-negative bacteria 29 28 1
   E. coli 15 14 1
   Pseudomonas aeruginosa 6 6
   Klebsiella pneumoniae 3 3
   Neisseria species (not 
meningitidis)
2 2
   Capnocytophaga species 2 2
   Enterobacter cloacae 1 1
FN episodes with bacteremia 67 60 7
TABLE 3. Effectiveness of Empiric Antibiotic Therapy in 67 FN Episodes With Bacteremia
Diagnostic Blood Culture Sampled 
≤48 h
Diagnostic Blood Culture Sampled 
>48 h All FN Episodes
In vitro (n = 58)* 44 of 54† 3 of 4‡ 47 of 58 (81%)
Due to compliance with pediatric FN 
guidelines (n = 58)*
53 of 54§ 3 of 4‡ 56 of 58 (96.6%)
Microbiologic (n = 67) 53 of 63¶ 0 of 4‖ 53 of 67 (79.1%)
*In 9 FN episodes, antimicrobial susceptibility testing was not available.
†Not effective in 8 CoNS, 1 Enterococcus faecalis, 1 VGS resistant to penicillin and ceftriaxone (further testing not available).
‡Not effective in 1 Enterococcus avium.
§Not effective in 1 VGS resistant to penicillin and ceftriaxone (further testing not available).
¶Not effective in 7 CoNS, 1 S. aureus, 1 VGS and 1 FN episode with persistent CoNS bacteremia and new E. coli bacteremia on day 3 of hospitalization
‖Not effective in 3 CoNS, 1 E. avium
FIGURE 1. Distribution of 
time to positivity of 33 blood 
cultures processed in center 
A according to microbiologic 
etiology.
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microbiologically proven in 29 (6.6%) of 441 FN episodes (in 25 
FN episodes by antigen detection and in 4 FN episodes by polymer-
ase chain reaction). In center A, the single center with a low-thresh-
old viral testing strategy, the proportion was 13% (23 of 171 FN 
episodes, 95% CI: 9–19%). In 16 FN episodes, an upper respiratory 
tract infection was diagnosed (1 adenovirus, later diagnosed with 
fatal systemic adenovirus infection,14 5 picornaviruses, 5 influenza 
A viruses, 1 influenza B virus, 1 parainfluenza virus, 2 respiratory 
syncytial viruses and 1 human metapneumovirus), in 6 FN episodes 
herpes simplex virus stomatitis was diagnosed, in 3 FN episodes a 
systemic viral infection was diagnosed (1 adenovirus, initially pre-
sented as respiratory tract infection,14 1 herpes simplex virus and 
1 cytomegalovirus), in 4 episodes a viral gastroenteritis was diag-
nosed (3 adenoviruses, 1 rotavirus) and in 1 FN episode herpes sim-
plex virus encephalitis was diagnosed. An invasive fungal infection 
was diagnosed in 5 FN episodes, in 2 FN episodes the fungal infec-
tion was histologically proven and in 3 probable (Table 5). All inva-
sive fungal infections were reported by center A, with a proportion 
of 2.9% (5 of 171, 95% CI: 1.1–6.4%).
DISCUSSION
The aim of this study was to describe all MDI detected in 
the prospective multicenter SPOG FN 2003 study. In many FN 
episodes (78%), no MDI was detected. Also, lack of MDI detection 
was associated with shorter duration of fever and hospitalization, 
less need of intensive care and less intensive antimicrobial therapy 
compared with FN episodes with MDI.
We detected MDI in around every fourth FN episode. Other 
studies of FN in pediatric cancer patients have reported comparable 
frequencies of MDI.15,16 Nevertheless, the perception that infections 
can be documented only in a minority of pediatric cancer patients 
with FN has been challenged by studies relying on systematic iden-
tification of viral infections by molecular methods.17–19 In 2 recent 
studies, MDI were detected in 67% and 60% of FN episodes, with 
respiratory virus infections being detected by molecular methods 
in 57% and 46% of FN episodes, respectively.17,18 This difference 
in the frequency of MDI is best explained by different diagnostic 
policies and procedures used for the detection of respiratory virus 
infections. In our study, even in the center with the most compre-
hensive strategy for respiratory virus diagnostics, viral infections 
were only documented in 13% of all FN episodes.
The detection of any MDI versus no MDI was clearly asso-
ciated with a more severe clinical course. The clinical course of FN 
episodes with bacteremia, however, did not relevantly differ from 
FN episodes with viral infection, except for a significantly longer 
administration and escalation of intravenous antibiotic therapy. The 
group with focal bacterial infections, fungal infections and mixed 
TABLE 4. Comparison of the Distribution of Pathogens Causing Bacteremia in the German-speaking Part of 
Switzerland Between Centers A, B and C of the SPOG 2003 FN Study and the General Pediatric Population (ANRESIS 
2004–2007)
Pathogen SPOG 2003 (n = 58) ANRESIS 2004–2007 (n = 378) P Value*
S. aureus 4 (6.9%) 64 (17%) 0.052
CoNS 12 (21%) 37 (9.8%) 0.023
S. pneumoniae 0 (0%) 89 (24%) <0.001
Viridans group streptococci 17 (29%) 35 (9.3%) <0.001
Streptococcus pyogenes 0 (0%) 6 (1.6%) 0.61
Enterococcus species 1 (1.7%) 11 (2.9%) 1
Enterobacteriaceae† 15 (26%) 90 (24%) 0.74
Pseudomonas aeruginosa 5 (8.6%) 22 (5.8%) 0.56
Neisseria species 1 (1.7%) 1 (0.3%) 0.24
Haemophilus influenzae 0 (0%) 6 (1.6%) 0.61
Moraxella catarrhalis 0 (0%) 1 (0.3%) 1
Others 3 (5.2%) 16 (4.2%) 0.72
Total 58 378
*Fisher exact test, not corrected for multiple testing. Overall comparison using Fisher-Freeman-Halton test, P < 0.001
†E. cloacae (1 in SPOG 2003 vs. 8 in ANRESIS), E. coli (11 vs. 40), Klebsiella species (3 vs. 16), Morganella morganii (0 vs. 2), Proteus species (0 vs. 4), Salmonella species (0 vs. 15), 
Citrobacter species (0 vs. 5)
TABLE 5. Invasive Fungal Infections Diagnosed in 5 of 441 FN Episodes
Type of  
Fungus Diagnostic Test
Sampling  
Location
Focal Disease 
Manifestation
Classification of 
Disease8
Day of  Diagnosis 
(From  Presentation 
With FN)
Oncologic 
 Diagnosis Outcome*
Aspergillus 
fumigatus
Galactomannan 
assay
Bronchial lavage Radiologic lung 
consolidation
Probable 7 ALL relapse Survived
Mucor species Histology Biopsy of nasal 
septum
Periorbital 
 cellulitis
Proven 11 PreB ALL Died from rhino 
cerebral 
 mucormycosis
A. fumigatus Galactomannan 
assay, PCR
Bronchial lavage Radiologic lung 
consolidation
Probable 13 ALL relapse Survived
Absidia 
 corymbifera
Culture Biopsy of nose and 
soft tissue of the 
face
Perinasal cellulitis Proven 4 AML Survived
A. fumigatus Galactomannan 
assay
Blood Radiologic lung 
consolidation
Probable 8 AML Survived
*The outcome of FN episodes was monitored until 7 days after completion of antimicrobial therapy and recovery of neutropenia.
ALL, acute lymphoblastic leukemia; AML, acute myeloid leukemia; PCR, polymerase chain reaction.
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infections showed a more severe clinical course but the heteroge-
neity of this group prevented further conclusions. Nevertheless, a 
more severe clinical course of mixed viral and bacterial infections 
in FN has been reported before.17,18,20
Bacteremia was the most frequent and most reliably detected 
MDI in this study. Similar to other studies of FN in pediatric cancer 
patients, Gram-positive pathogens, mainly CoNS and VGS, con-
stituted many isolated pathogens.15,16,21 E. coli was the most fre-
quent Gram-negative pathogen causing bacteremia. As expected, 
the frequency of CoNS and VGS bacteremia differed significantly 
in patients with cancer and FN compared with the general pediatric 
population. Surprisingly, bacteremia caused by S. pneumoniae was 
not identified in our study population. Although, this contrasts with 
the general notion of cancer as a risk factor for invasive pneumo-
coccal disease,22–24 it is strongly in line with other studies of pedi-
atric cancer patients with FN.15,16,25 In other patient populations, 
repetitive antibiotic therapy has been shown to reduce the carriage 
of S. pneumoniae, whereas the effect of cotrimoxazole prophylaxis 
was less clear.26 It is unlikely that vaccination against S. pneumo-
niae played a role in this study as the Swiss Federal Office of Pub-
lic Health first issued a general recommendation for pneumococcal 
vaccination of children <5 years of age only in 2006, and pediatric 
cancer patients were not specifically vaccinated against S. pneumo-
niae before chemotherapy start in this study.
In a subset of FN episodes with bacteremia, a short time 
to positivity for both Gram-positive, with the exception of CoNS, 
and Gram-negative pathogens was observed. Comparable results 
have been reported and may favor an initial inpatient treatment 
period of 24 hours for the evaluation of chemotherapy induced 
FN in pediatric cancer patients.15 It should be noted, however, 
that in the SPOG 2003 FN study, bacteremia was first detected 
in a subsequent blood culture in 11 (2.5%) of 441 FN episodes 
(16% of 67 FN episodes with bacteremia).4 A negative initial 
blood culture 24 hours after patient admission rendered a viru-
lent Gram-negative or  Gram-positive bacteremia unlikely but did 
not exclude bacteremia as such.
The effectiveness of empiric antibiotic therapy because of 
compliance with pediatric FN guidelines was high in this study. 
Nevertheless, in one FN episode, Gram-negative bacteremia was 
detected on the third day of hospitalization only. In this patient, gly-
copeptide monotherapy had been started because of clinical signs of 
catheter infection, clearly not fulfilling the predefined requirements 
on initial empiric antibiotic therapy in pediatric cancer patients 
with FN. Although CoNS bacteremia was proven in the blood cul-
ture sampled at presentation and on the catheter tip removed on the 
third day of hospitalization, E. coli bacteremia was identified in a 
blood culture sampled on the third day. This underlines once more 
the importance of empiric coverage of Gram-negative pathogens by 
the initial antibiotic therapy of FN.
CoNS bacteremia was the main reason for failure of empiric 
antibiotic therapy in this study. Empiric addition of glycopeptides 
to the first-line empiric therapy has been evaluated in adult patients 
with cancer, but was not found to be superior to standard regimens 
in a meta-analysis.27 Escalation of antibiotic therapy to include cov-
erage for CoNS is recommended in pediatric cancer patients if fever 
persists for >24–72 hours, and they become clinically unstable.9,10
In this study, antibiotic therapy was escalated in almost 
 one-third of FN episodes without MDI. Unfortunately, it was not 
possible to reliably determine in how many of these episodes no 
deterioration of clinical condition, and thereby overtreatment, 
occurred.
This study has several limitations. First, this was an ad hoc 
analysis for which the SPOG 2003 FN study was not designed 
for. Specifically, besides sampling of blood cultures all other 
microbiologic investigations, diagnostic modalities and clinical 
care practices were at the discretion of the treating physician. The 
low number of focal bacterial infections and viral infections identi-
fied in this study likely underestimates the actual burden of these 
MDI. Second, not all centers in this prospective multicenter study 
recruited patients consecutively and over the complete study dura-
tion. This may additionally favor underestimation of the burden of 
MDI, especially invasive fungal infections. Third, some analyses 
presented, for example, time to positivity, could only be performed 
in subgroups of the study population because of different labora-
tory data collection practices.
In this study, MDI were identified in only a minority of FN 
episodes but they significantly affected management and the clini-
cal course of patients. Compliance with recently published guide-
lines9,10 was associated with effectiveness of empiric antibiotic 
therapy in FN episodes with bacteremia.
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